Length of Positive Surgical Margin After Radical Prostatectomy as a Predictor of Biochemical Recurrence
Purpose
Length and location of positive surgical margins are independent predictors of biochemical recurrence after open radical prostatectomy. We assessed their impact on biochemical recurrence in a large robotic prostatectomy series.
Materials and Methods
Data were collected prospectively from 1,398 men undergoing robotic radical prostatectomy for clinically localized prostate cancer from 2003 to 2008 at a single institution. The associations of preoperative prostate specific antigen, pathological Gleason score, pathological stage and positive surgical margin parameters (location, length and focality) with biochemical recurrence rate were evaluated. Margin status and length were measured by a single uropathologist. Biochemical recurrence was defined as serum prostate specific antigen greater than 0.1 ng/ml on 2 consecutive tests. Cox regression models were constructed to evaluate predictors of biochemical recurrence.
Results
Of 1,398 consecutive patients who underwent robotic prostatectomy positive margins were present in 243 (17%) (11% of pathological T2 and 41% of T3). Preoperative prostate specific antigen, pathological stage, Gleason score, margin status, and margin length as a continuous and categorical variable (less than 1, 1 to 3, more than 3 mm) were independent predictors of biochemical recurrence. Patients with negative margins and those with a positive margin less than 1 mm had similar rates of biochemical recurrence (log rank test p = 0.18). Surgical margin location was not independently associated with biochemical recurrence.
Conclusions
Margin status and length are independent predictors of biochemical recurrence following robotic radical prostatectomy. Although longer followup and validation studies are necessary for confirmation, patients with a positive margin less than 1 mm appear to have similar recurrence rates as those with negative margins.
Key Words: prostatectomy, recurrence
Abbreviations and Acronyms: BCR, biochemical recurrence, BMI, body mass index, ECE, extracapsular extension, GS, Gleason score, PSA, prostate specific antigen, PSM, positive surgical margin, RP, radical prostatectomy
To access this article, please choose from the options below
Editor's Note: This article is the third of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 402 and 403.
For another article on a related topic see page 317.
PII: S0022-5347(09)00577-1
doi:10.1016/j.juro.2009.02.139
© 2009 American Urological Association. Published by Elsevier Inc. All rights reserved.
Refers to article:
- Phase II Trial of Capecitabine and Weekly Docetaxel for Metastatic Castrate Resistant Prostate Cancer , 18 May 2009

